On October 21, Novo Nordisk announced positive news on the cardiovascular benefits of its oral GLP-1R agonist, Rybelsus, ...

Over the past few days at the 128th Annual Meeting of the American Academy of Ophthalmology (AAO) 2024 in Chicago, US, the ...

As groundbreaking studies continue to reshape the human immunodeficiency virus (HIV) landscape, emerging therapies and ...

The study will evaluate the company’s Gen-3 Halo headset as an at-home treatment for mild traumatic brain injury.

Otsuka has reported positive interim results from its Phase III trial evaluating sibeprenlimab, a treatment for adults with ...